Acorda Therapeutics, Inc. (CDG.F)
Acorda Therapeutics, Inc.
2 Blue Hill Plaza
3rd Floor
Pearl River, NY 10965
United States
914 347 4300
https://www.acorda.com
Sector(es):
Industria:
Empleados a tiempo completo: 102
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Ron Cohen M.D. | Founder, CEO, President & Director | 829.84k | N/D | 1956 |
| Mr. Michael A. Gesser M.B.A. | CFO & Treasurer | 565.51k | N/D | 1963 |
| Mr. Neil S. Belloff Esq. | General Counsel & Corporate Secretary | 569.88k | N/D | 1960 |
| Ms. Denise J. Duca | Executive Vice President of Human Resources | N/D | N/D | N/D |
| Mr. Kerry M. Clem | Chief Commercial Officer | 547.64k | N/D | 1970 |
| Sofia Ali | Senior VP of Operations & Strategic Planning | N/D | N/D | N/D |
| Susan Way | Senior VP of Drug Development & Regulatory Affairs | N/D | N/D | N/D |
| Dr. Wise Young M.D., Ph.D. | Special Scientific Advisor | 9.25k | N/D | 1950 |
Descripción
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Gestión corporativa
La calificación ISS Governance QuickScore de Acorda Therapeutics, Inc. a partir del 1 de mayo de 2024 es 7. Las puntuaciones principales son Auditoría: 9; Junta: 5; Derechos del accionista: 7; Compensación: 7.
